Review of Natural Product-Derived Compounds as Potent Antiglioblastoma Drugs

Table 7

Clinical trial of natural products.

Phase	Title	Current state	Family names	Medical plants	Compounds/extracts	Additional therapy	Evaluation	Survival	Patients	References
Phase 1,; Phase 2	Patupilone (EPO 906) in patients with recurrent or progressive glioblastoma multiforme prior to and after secondary resection: an open-label phase I/II trial	Completed	Myxobacterium	Sorangium cellulosum	Patupilone	Salvage treatment after patupilone consisted of bevacizumab, CCNU, a second RT round or surgery	Progression-free survival (PFS), overall survival (OS) at 6 months, patupilone concentration in tumor tissue/toxicity, patupilone concentration in plasma and translational analyses for predictive biomarkers, Aschen Aphasia Test, Rey Auditory-Verbal Learning Test, Rey Visual Design Learning Test, Rey-Osterrieth Complex analyses for predictive biomarkers	Median 85 weeks/median PFS 6 weeks	9 patients/age 42–68 yrs	[92]
Phase 2	Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma	Completed	Enterobacteriaceae	Serratia marcescens	ImuVert	Radiation therapy	Physical examination, KPS, assessment of weight, CBC count with differential, coagulation profile, serum chemistries, CT, MRI, thallium SPECT, time to progression of tumor	Median survival 69 weeks/median time to progression 11 weeks	11 patients/newly diagnosed glioblastoma multiforme (GBM)/age 42–69 yrs	[93]